Developer docs
API playgroundTry for free, no card

Search company profiles

Eyevensys

Full company profile

uuid00028nt

Namestring
Eyevensys
Legal namestring
PulseSight Therapeutics
Websiteurl
eyevensys.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Eyevensys, now operating as PulseSight Therapeutics, is a clinical-stage biotechnology company founded in 2008 and headquartered in Paris, France. The company is developing non-viral gene therapies dedicated to ophthalmology, targeting severe retinal diseases that lead to blindness. Its pipeline centers on age-related macular degeneration (AMD), geographic atrophy (GA), wet AMD, retinitis pigmentosa, and choroideremia. Lead clinical candidates include PST-611 for dry AMD/Geographic Atrophy (currently in Phase I, with positive interim data presented at ARVO 2026 in May 2026) and PST-809 for AMD.

The company's core technology is a proprietary non-viral gene therapy platform purpose-built for ophthalmic delivery, positioning it as a domain specialist distinct from viral-vector gene therapy competitors. This platform is designed to deliver therapeutic genes to ocular tissues to address degenerative retinal conditions with limited current treatment options. The company operates through traditional biotech commercialization pathways — eventual revenue is expected to flow through specialty healthcare channels (treatment centers, specialty pharmacies) post-regulatory approval, with licensing/royalties as the implied revenue model.

Eyevensys/PulseSight is pre-revenue and venture capital-backed, having raised approximately $52 million cumulatively across multiple Series B-tranche rounds between 2015 and 2021, led successively by Pontifax, Boehringer Ingelheim Venture Fund, and Korea Investment Partners. The company has a lean headcount of 11–50 employees and a leadership team with deep ophthalmology and clinical development expertise, including founder Francine Behar-Cohen serving as Chief Innovation Officer. It was recognized in 2025 as one of the "100 Cell and Gene Therapy Leaders to Watch."

Short descriptiontext

PulseSight Therapeutics (formerly Eyevensys) is a clinical-stage biotech developing non-viral gene therapies for ophthalmology, targeting age-related macular degeneration, geographic atrophy, retinitis pigmentosa, and choroideremia. Its pipeline includes PST-611 and PST-809.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
ophthalmic gene therapy, non-viral gene delivery, retinal disease therapeutics, age-related macular degeneration, geographic atrophy treatment
Industry3 codes
PRIMARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Ophthalmic Gene Therapy Biopharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Gene Therapy Pipeline
TypeLicensing Royalties
Description

Pre-commercial biotech company developing gene therapy treatments for ophthalmology. Revenue model will likely involve pharmaceutical/biotech commercialization through healthcare channels upon regulatory approval.

finsmes.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1PST-611
Description

Gene therapy product for dry AMD/Geographic Atrophy in clinical development

pulsesight.com
+1 more record
Core offering1 text field

Eyevensys (operating as PulseSight Therapeutics) is a clinical-stage biotechnology company developing non-viral gene therapies dedicated to ophthalmology. Its core offerings are investigational gene therapy product candidates — PST-611 for dry AMD/geographic atrophy and PST-809 for wet AMD — designed to treat severe retinal diseases leading to blindness through a proprietary non-viral gene delivery platform.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Eyevensys is a biotechnology company developing gene therapies for eye diseases. The company is focused on developing non-viral gene therapy solutions targeting age-related macular degeneration (AMD), geographic atrophy, and retinitis pigmentosa. Specific named products or therapeutic candidates have not been disclosed in the available source data.

Product and service2 records
1PST-611
CategoryOphthalmic Gene Therapy
Description

Investigational non-viral gene therapy product candidate for patients with dry age-related macular degeneration (dry AMD) and geographic atrophy (GA), severe retinal diseases that lead to blindness. Developed for administration by ophthalmology specialists in clinical settings.

2PST-809
CategoryOphthalmic Gene Therapy
Description

Pipeline-stage investigational gene therapy candidate for age-related macular degeneration (AMD), being developed using Eyevensys/PulseSight's proprietary non-viral gene delivery platform.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage gene therapy company with ophthalmology programs including treatments for inherited retinal diseases and AMD. Directly comparable as a clinical-stage gene therapy peer in ophthalmology.

TypeBroad incumbent
Description

Developed Izervay (avacincaptad pegol), an FDA-approved C5 inhibitor for geographic atrophy. Acquired by Astellas — represents the established standard-of-care competitor in PulseSight's PST-611 GA indication.

TypeDirect peer
Description

Clinical-stage biotech developing ADVM-022, an AAV-based gene therapy for wet AMD. Competes directly with PulseSight in ophthalmology gene therapy with similar target indications and delivery approach.

TypeBroad incumbent
Description

Biopharmaceutical company with ophthalmology franchise including Cimerli (ranibizumab biosimilar) competing in wet AMD market. Represents competitive commercial pressure on PulseSight's PST-809 wet AMD indication.

TypeDirect peer
Description

Clinical-stage gene therapy company developing 4D-150 for wet AMD and other ophthalmology indications. Direct competitor with proprietary AAV platform targeting the same indications as PulseSight.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based therapies including RGX-314 for wet AMD. Most direct competitor to PulseSight in ophthalmology gene therapy targeting AMD.

TypeDirect peer
Description

Clinical-stage biotech developing GS010, a gene therapy for Leber's Hereditary Optic Neuropathy (LHON). Direct peer in ophthalmology gene therapy with similar regulatory and clinical pathway considerations.

TypeBroad incumbent
Description

Developed GT005, a gene therapy for geographic atrophy. Acquired by Novartis in 2022 — represents a strategic exit path and validates M&A appetite for ophthalmology gene therapy assets.

TypeBroad incumbent
Description

Developer and marketer of Luxturna, the first FDA-approved gene therapy for inherited retinal disease. Acquired by Roche, serves as the broad incumbent benchmark for ophthalmology gene therapy commercialization.

TypeEmerging player
Description

Emerging clinical-stage ophthalmology company developing small molecule and gene therapy approaches for retinal diseases including retinitis pigmentosa. Adjacent peer with overlapping indications but different modality.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Eyevensys

Ophthalmic Gene Therapy Biopharmaceuticalseyevensys.com

PulseSight Therapeutics (formerly Eyevensys) is a clinical-stage biotech developing non-viral gene therapies for ophthalmology, targeting age-related macular degeneration, geographic atrophy, retinitis pigmentosa, and choroideremia. Its pipeline includes PST-611 and PST-809.

What Eyevensys does

Eyevensys, now operating as PulseSight Therapeutics, is a clinical-stage biotechnology company founded in 2008 and headquartered in Paris, France. The company is developing non-viral gene therapies dedicated to ophthalmology, targeting severe retinal diseases that lead to blindness. Its pipeline centers on age-related macular degeneration (AMD), geographic atrophy (GA), wet AMD, retinitis pigmentosa, and choroideremia. Lead clinical candidates include PST-611 for dry AMD/Geographic Atrophy (currently in Phase I, with positive interim data presented at ARVO 2026 in May 2026) and PST-809 for AMD.

The company's core technology is a proprietary non-viral gene therapy platform purpose-built for ophthalmic delivery, positioning it as a domain specialist distinct from viral-vector gene therapy competitors. This platform is designed to deliver therapeutic genes to ocular tissues to address degenerative retinal conditions with limited current treatment options. The company operates through traditional biotech commercialization pathways — eventual revenue is expected to flow through specialty healthcare channels (treatment centers, specialty pharmacies) post-regulatory approval, with licensing/royalties as the implied revenue model.

Eyevensys/PulseSight is pre-revenue and venture capital-backed, having raised approximately $52 million cumulatively across multiple Series B-tranche rounds between 2015 and 2021, led successively by Pontifax, Boehringer Ingelheim Venture Fund, and Korea Investment Partners. The company has a lean headcount of 11–50 employees and a leadership team with deep ophthalmology and clinical development expertise, including founder Francine Behar-Cohen serving as Chief Innovation Officer. It was recognized in 2025 as one of the "100 Cell and Gene Therapy Leaders to Watch."

Eyevensys firmographics

Firmographics
Name
Eyevensys
Legal name
PulseSight Therapeutics
Website
https://eyevensys.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
PulseSight Therapeutics (formerly Eyevensys) is a clinical-stage biotech developing non-viral gene therapies for ophthalmology, targeting age-related macular degeneration, geographic atrophy, retinitis pigmentosa, and choroideremia. Its pipeline includes PST-611 and PST-809.
Ownership category
akta.pro rank

Eyevensys industry classification

Industry
Product category
Ophthalmic Gene Therapy Biopharmaceuticals
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals

Keywords

  • Ophthalmic gene therapy
  • Non-viral gene delivery
  • Retinal disease therapeutics
  • Age-related macular degeneration
  • Geographic atrophy treatment

Where Eyevensys is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Markets served

Eyevensys business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Gene Therapy Pipeline: Pre-commercial biotech company developing gene therapy treatments for ophthalmology. Revenue model will likely involve pharmaceutical/biotech commercialization through healthcare channels upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Eyevensys product offering

Product offering

Core offering

Eyevensys (operating as PulseSight Therapeutics) is a clinical-stage biotechnology company developing non-viral gene therapies dedicated to ophthalmology. Its core offerings are investigational gene therapy product candidates — PST-611 for dry AMD/geographic atrophy and PST-809 for wet AMD — designed to treat severe retinal diseases leading to blindness through a proprietary non-viral gene delivery platform.

Product overview

Eyevensys is a biotechnology company developing gene therapies for eye diseases. The company is focused on developing non-viral gene therapy solutions targeting age-related macular degeneration (AMD), geographic atrophy, and retinitis pigmentosa. Specific named products or therapeutic candidates have not been disclosed in the available source data.

Differentiator

Problem solved

Functional benefit

Brands

  • PST-611: Gene therapy product for dry AMD/Geographic Atrophy in clinical development
  • PST-809

Products and services

  • PST-611 Investigational non-viral gene therapy product candidate for patients with dry age-related macular degeneration (dry AMD) and geographic atrophy (GA), severe retinal diseases that lead to blindness. Developed for administration by ophthalmology specialists in clinical settings.
  • PST-809 Pipeline-stage investigational gene therapy candidate for age-related macular degeneration (AMD), being developed using Eyevensys/PulseSight's proprietary non-viral gene delivery platform.

Companies that use Eyevensys

Customer profile

Segments1 record

Ideal customer profiles1 record

Eyevensys technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Eyevensys partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Eyevensys competitors and assessment

Company assessment

Direct peers

  • MeiraGTx: Clinical-stage gene therapy company with ophthalmology programs including treatments for inherited retinal diseases and AMD. Directly comparable as a clinical-stage gene therapy peer in ophthalmology.
  • Adverum Biotechnologies: Clinical-stage biotech developing ADVM-022, an AAV-based gene therapy for wet AMD. Competes directly with PulseSight in ophthalmology gene therapy with similar target indications and delivery approach.
  • 4D Molecular Therapeutics: Clinical-stage gene therapy company developing 4D-150 for wet AMD and other ophthalmology indications. Direct competitor with proprietary AAV platform targeting the same indications as PulseSight.
  • REGENXBIO: Clinical-stage gene therapy company developing AAV-based therapies including RGX-314 for wet AMD. Most direct competitor to PulseSight in ophthalmology gene therapy targeting AMD.
  • GenSight Biologics: Clinical-stage biotech developing GS010, a gene therapy for Leber's Hereditary Optic Neuropathy (LHON). Direct peer in ophthalmology gene therapy with similar regulatory and clinical pathway considerations.

Broad incumbents

  • Iveric Bio (Astellas): Developed Izervay (avacincaptad pegol), an FDA-approved C5 inhibitor for geographic atrophy. Acquired by Astellas — represents the established standard-of-care competitor in PulseSight's PST-611 GA indication.
  • Coherus BioSciences: Biopharmaceutical company with ophthalmology franchise including Cimerli (ranibizumab biosimilar) competing in wet AMD market. Represents competitive commercial pressure on PulseSight's PST-809 wet AMD indication.
  • Gyroscope Therapeutics (Novartis): Developed GT005, a gene therapy for geographic atrophy. Acquired by Novartis in 2022 — represents a strategic exit path and validates M&A appetite for ophthalmology gene therapy assets.
  • Spark Therapeutics (Roche): Developer and marketer of Luxturna, the first FDA-approved gene therapy for inherited retinal disease. Acquired by Roche, serves as the broad incumbent benchmark for ophthalmology gene therapy commercialization.

Emerging players

  • Kiora Pharmaceuticals: Emerging clinical-stage ophthalmology company developing small molecule and gene therapy approaches for retinal diseases including retinitis pigmentosa. Adjacent peer with overlapping indications but different modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Eyevensys financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Eyevensys leadership team

Management profile

Number of profiles

Profiles5 records

Eyevensys funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Eyevensys M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eyevensys

What does Eyevensys do?

Eyevensys (operating as PulseSight Therapeutics) is a clinical-stage biotechnology company developing non-viral gene therapies dedicated to ophthalmology. Its core offerings are investigational gene therapy product candidates — PST-611 for dry AMD/geographic atrophy and PST-809 for wet AMD — designed to treat severe retinal diseases leading to blindness through a proprietary non-viral gene delivery platform.

Is Eyevensys a public or private company?

Eyevensys is a private company. It is classified as venture growth investor backed and is currently operating.

When was Eyevensys founded?

Eyevensys was founded in 2008. It employs 11 to 50 people.

Where is Eyevensys based?

Eyevensys is headquartered in Paris, France, in the Europe region.

How does Eyevensys make money?

One revenue line is on record: gene Therapy Pipeline.

Who are Eyevensys's main competitors?

Direct peers on record are MeiraGTx, Adverum Biotechnologies, 4D Molecular Therapeutics, REGENXBIO and GenSight Biologics. Broad incumbents are Iveric Bio (Astellas), Coherus BioSciences, Gyroscope Therapeutics (Novartis) and Spark Therapeutics (Roche). Kiora Pharmaceuticals is listed as an emerging player.

Does Eyevensys have an API?

No public API is recorded for Eyevensys.

What industry is Eyevensys in?

Eyevensys's product category is Ophthalmic Gene Therapy Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAG, Ophthalmology Gene Therapies, with a secondary code of HLAIAIAK, Rare Ophthalmology Disorder Therapies. Its NAICS code is 334510 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceEyevensys Enters Collaboration with Phillips-Medisize and Minnetronix MedicalEyevensys announced strategic engagements with Phillips-Medisize and Minnetronix Medical to develop its next-generation ocular device and pulse generator. The companies will optimize design and support high-volume manufacturing for the Electrotransfection System. Work has been initiated at both contract manufacturers.Business Wire BlogEyevensys Enters Collaboration with Phillips-Medisize and Minnetronix MedicalEyevensys announced strategic engagements with Phillips-Medisize and Minnetronix Medical to develop next-generation components of its ocular device and electrical pulse generator. The companies will optimize design and support high-volume manufacturing for the Electrotransfection System. Work has been initiated at both contract manufacturers.FinSMEsEyevensys Raises $12M in Series B+ FundingEyevensys, a Paris and Cambridge-based biotechnology firm developing non-viral gene therapies for eye disease, raised $12 million in Series B+ funding led by Korea Investment Partners. The company will use the money to advance its EYS809 program for wet age-related macular degeneration and its EYS611 program for geographic atrophy and retinitis pigmentosa.Business Wire BlogEyevensys Raises $12M in a Series B Plus Funding RoundEyevensys raised $12M in a Series B Plus funding round led by Korea Investment Partners. The funds will accelerate development of its EYS809 program for wet AMD and EYS611 for geographic atrophy and retinitis pigmentosa. The company will use its non-viral gene therapy platform to deliver therapeutic proteins to the eye.Business Wire BlogEyevensys Raises $12M in a Series B Plus Funding RoundEyevensys raised $12M in a Series B Plus funding round led by Korea Investment Partners. The funds will accelerate development of its EYS809 program for wet AMD and EYS611 for geographic atrophy and retinitis pigmentosa. The company's non-viral gene therapy platform uses electrotransfection to deliver therapeutic proteins.FinSMEsEyevensys Raises $30M in Series B FinancingEyevensys, a Paris-based biotech developing non-viral gene therapies for eye diseases, raised $30M in Series B financing led by Boehringer Ingelheim Venture Fund. The funds will advance its clinical lead EYS606 for chronic non-infectious uveitis and preclinical development of other ophthalmic treatments. The company also opened a U.S. subsidiary in Fort Worth, Texas.PR NewswireEyevensys Appoints New Board Member, Gerald CagleEyevensys, a clinical-stage biotech company based in Paris developing non-viral gene therapies for ophthalmic diseases, announced the appointment of Gerald Cagle to its Board of Directors. Cagle previously served as Senior Vice President and Chief Scientific Officer at Alcon Laboratories for 13 years and brings nearly 40 years of pharmaceutical industry experience along with 28 issued patents. His appointment is expected to support the advancement of Eyevensys' EyeCET platform and its lead product EYS606, currently in Phase I/II clinical trials for the treatment of non-infectious uveitis.PR NewswireEyevensys Appoints Dr. Patricia Zilliox as Chief Executive OfficerEyevensys, a Paris-based clinical stage biotech company developing non-viral gene therapies for ophthalmic diseases, announced the appointment of Dr. Patricia Zilliox as its new Chief Executive Officer. Dr. Zilliox brings more than 25 years of global clinical development expertise in ophthalmology, having previously led clinical programs at Alcon Laboratories and served as Chief Drug Development Officer at the Foundation Fighting Blindness. She succeeds Raffy Kazandjian and will focus on advancing the company's lead product EYS606 through clinical trials and expanding its EyeCET gene therapy platform.PR NewswireEyevensys Appoints Thierry Bordet Ph.D. as Pre-clinical DirectorEyevensys, a clinical-stage biotech company based in Paris, announced the appointment of Thierry Bordet, Ph.D. as Pre-Clinical Director to oversee the company's pre-clinical development efforts targeting eye diseases such as retinal vein occlusion and retinitis pigmentosa. Bordet brings more than 15 years of experience in the biotechnological sector, having previously served as Pre-Clinical Development Director at the Biotherapies Institute for Rare Diseases in France and spent 12 years at Trophos managing drug screening programs. The CEO stated that Bordet's expertise in gene therapies and pre-clinical research will help advance several of Eyevensys' products through development.